In addition, although JQ1 stimulated anti-HCC activity in vitro, treatment with JQ1 at 50 mg/kg twice daily in vivo had only a modest effect on tumor growth, suggesting that BRD4 inhibitors with increased bioavailability or potency may be required for improved therapeutic responses [33]. The gene discussed is BRD4; the disease is hepatocellular carcinoma.